These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 15340100

  • 1. Current and investigational antiobesity agents and obesity therapeutic treatment targets.
    Bays HE.
    Obes Res; 2004 Aug; 12(8):1197-211. PubMed ID: 15340100
    [Abstract] [Full Text] [Related]

  • 2. Investigational therapies in the treatment of obesity.
    Mancini MC, Halpern A.
    Expert Opin Investig Drugs; 2006 Aug; 15(8):897-915. PubMed ID: 16859393
    [Abstract] [Full Text] [Related]

  • 3. [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].
    Zieba R.
    Postepy Hig Med Dosw (Online); 2007 Oct 19; 61():612-26. PubMed ID: 17971763
    [Abstract] [Full Text] [Related]

  • 4. Obesity: new perspectives and pharmacotherapies.
    Palamara KL, Mogul HR, Peterson SJ, Frishman WH.
    Cardiol Rev; 2006 Oct 19; 14(5):238-58. PubMed ID: 16924165
    [Abstract] [Full Text] [Related]

  • 5. Thermogenic and metabolic antiobesity drugs: rationale and opportunities.
    Clapham JC, Arch JR.
    Diabetes Obes Metab; 2007 May 19; 9(3):259-75. PubMed ID: 17391151
    [Abstract] [Full Text] [Related]

  • 6. New targets for obesity pharmacotherapy.
    Aronne LJ, Thornton-Jones ZD.
    Clin Pharmacol Ther; 2007 May 19; 81(5):748-52. PubMed ID: 17438540
    [Abstract] [Full Text] [Related]

  • 7. Neuroendocrine control of food intake.
    Valassi E, Scacchi M, Cavagnini F.
    Nutr Metab Cardiovasc Dis; 2008 Feb 19; 18(2):158-68. PubMed ID: 18061414
    [Abstract] [Full Text] [Related]

  • 8. Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines.
    Correia ML, Haynes WG.
    Expert Opin Emerg Drugs; 2005 Aug 19; 10(3):643-60. PubMed ID: 16083333
    [Abstract] [Full Text] [Related]

  • 9. Emerging therapeutic strategies for obesity.
    Foster-Schubert KE, Cummings DE.
    Endocr Rev; 2006 Dec 19; 27(7):779-93. PubMed ID: 17122357
    [Abstract] [Full Text] [Related]

  • 10. Adipose tissue as an endocrine organ.
    Ahima RS.
    Obesity (Silver Spring); 2006 Aug 19; 14 Suppl 5():242S-249S. PubMed ID: 17021375
    [Abstract] [Full Text] [Related]

  • 11. Design and synthesis of (ant)-agonists that alter appetite and adiposity.
    Van der Ploeg LH, Kanatani A, MacNeil D, Ming Fong T, Strack A, Nargund R, Guan XM.
    Prog Brain Res; 2006 Aug 19; 153():107-18. PubMed ID: 16876570
    [Abstract] [Full Text] [Related]

  • 12. [Physiological and neurobiological aspects of eating].
    Costentin J.
    Bull Acad Natl Med; 2003 Aug 19; 187(7):1367-76; discussion 1376-7. PubMed ID: 15146610
    [Abstract] [Full Text] [Related]

  • 13. Obesity Drug Development Summit. 21-22 July, 2005, Arlington, VA, USA.
    Maggio CA.
    IDrugs; 2005 Sep 19; 8(9):701-3. PubMed ID: 16118685
    [Abstract] [Full Text] [Related]

  • 14. Plasma and hypothalamic peptide-hormone levels regulating somatotroph function and energy balance in fed and fasted states: a comparative study in four strains of rats.
    Kappeler L, Zizzari P, Grouselle D, Epelbaum J, Bluet-Pajot MT.
    J Neuroendocrinol; 2004 Dec 19; 16(12):980-8. PubMed ID: 15667453
    [Abstract] [Full Text] [Related]

  • 15. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?
    Bays H, Blonde L, Rosenson R.
    Expert Rev Cardiovasc Ther; 2006 Nov 19; 4(6):871-95. PubMed ID: 17173503
    [Abstract] [Full Text] [Related]

  • 16. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors.
    Jensen MD.
    Obesity (Silver Spring); 2006 Jun 19; 14 Suppl 3():143S-149S. PubMed ID: 16931496
    [Abstract] [Full Text] [Related]

  • 17. Newly approved and promising antidiabetic agents.
    Combettes M, Kargar C.
    Therapie; 2007 Jun 19; 62(4):293-310. PubMed ID: 17983555
    [Abstract] [Full Text] [Related]

  • 18. [Molecular targets for new drug discovery to treat type 2 diabetes and obesity].
    Bastarrachea RA, Montero JC, Saavedra-Gajardo I, Cerda-Flores R, Machado-Domínguez A, Comuzzie AG.
    Rev Med Chil; 2008 Jan 19; 136(1):107-17. PubMed ID: 18483661
    [Abstract] [Full Text] [Related]

  • 19. Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.
    Srivastava G, Apovian C.
    Curr Obes Rep; 2018 Jun 19; 7(2):147-161. PubMed ID: 29504049
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus.
    Koren S, Fantus IG.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec 19; 21(4):621-40. PubMed ID: 18054739
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.